At present, the first-line therapeutic agents for CPP are GnRH analogs (Bertelloni and Baroncelli, 2013), which inhibit gonadotropin secretion and negatively mediate GnRH receptors, leading to a reduction in the levels of gonadal steroids to prepubertal levels (Bertelloni et al., 2018). This evidence concerns the gene GNRH1 and central precocious puberty.